Exportin 1/chromosome region maintenance 1 as a therapeutic target for lung cancer

Por Gao, Weimin
Publicado no Transl Cancer Res (2017)

Tumor lymphocytic infiltration in non-small cell lung cancer: the ultimate prognostic marker?

Por Romero Vielva, Laura
Publicado no Transl Lung Cancer Res (2016)

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Por Costa, Daniel B.
Publicado no Transl Lung Cancer Res (2014)

Professor Robert Pirker: primary prevention and early detection of lung cancer should be strengthened

Por He, Melanie C.
Publicado no Transl Lung Cancer Res (2015)

KEYNOTE-028: how do we use immunotherapy in small cell lung cancer?

Por Pacheco, Jose M., Camidge, D. Ross
Publicado no Transl Lung Cancer Res (2017)

Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer

Por Xie, Hao, Adjei, Alex A.
Publicado no Transl Lung Cancer Res (2017)

The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?

Por Troncone, Giancarlo, Gridelli, Cesare
Publicado no Transl Lung Cancer Res (2017)

Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option

Por Passaro, Antonio, de Marinis, Filippo
Publicado no Transl Lung Cancer Res (2018)

Targeting IL22: a potential therapeutic approach for Kras mutant lung cancer?

Por Weinberg, Frank D., Ramnath, Nithya
Publicado no Transl Lung Cancer Res (2018)

A novel biomarker protein panel for lung cancer, a promising first step

Por Molina-Romero, Camilo, Vergara, Edgar, Arrieta, Oscar
Publicado no Transl Lung Cancer Res (2018)

Old myths about old patients: the case of non-small cell lung cancer

Por Pinto, Joseph A., Raez, Luis E.
Publicado no Transl Lung Cancer Res (2018)

The combination strategies will be ready the right first-line choice for squamous lung cancer patients?

Por Gridelli, Cesare, Casaluce, Francesca
Publicado no Transl Lung Cancer Res (2018)

Neoadjuvant EGFR TKIs: toward personalized management in non-small-cell lung cancer

Por Passaro, Antonio, Cortesi, Enrico
Publicado no Transl Lung Cancer Res (2012)

Antiangiogenic tyrosine kinase inhibitors in non-small-cell-lung cancer: lights and shadows

Por Gasparini, Giampietro
Publicado no Transl Lung Cancer Res (2013)

Anatomic segmentectomy for non-small cell lung cancer: can we believe the hype?

Por Chan, Ernest G., D’Cunha, Jonathan
Publicado no Transl Lung Cancer Res (2015)

Potential future consideration for imaging and blood-based biomarkers for precision medicine in lung cancer

Por Kong, Feng-Ming (Spring), Hirsch, Fred R., Machtay, Mitchell
Publicado no Transl Lung Cancer Res (2017)

Emerging resistance pathways in lung cancer: what has ROS-1 taught us?

Por Alrifai, Doraid, Forster, Martin D., Janes, Sam M.
Publicado no Transl Lung Cancer Res (2018)

Hunting for transcription factors: STAT3 decoy in non-small cell lung cancer

Por Carmicheal, Joseph, Kaur, Sukhwinder, Batra, Surinder K., Ganti, Apar Kishor
Publicado no Transl Lung Cancer Res (2018)

Gene therapy for lung cancer malignant pleural effusion: current and future nano-biotechnology

Por Zarogoulidis, Paul, Domvri, Kalliopi, Huang, Haidong, Zarogoulidis, Konstantinos
Publicado no Transl Lung Cancer Res (2012)

The impact of patients’ preferences on the decision of low-dose computed tomography lung cancer screening

Por Wu, Fu-Zong, Kuo, Pei-Lun, Wu, Carol C., Wu, Ming-Ting
Publicado no Transl Lung Cancer Res (2018)